================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest reported) January 22, 2001
------------------------------------
QUEST BIOTECHNOLOGY, INC.
--------------------------------------------------------------------------------
(Exact name of small business issuer as specified in its charter)
Commission file number 0-15489
-------
MICHIGAN 0-15489 38-2656058
--------------------------------------------------------------------------------
(State or other jurisdiction of (Commission (IRS Employer
incorporation or organization) File Number) Identification No.)
321 FISHER BUILDING, 3011 W. GRAND BLVD., DETROIT, MICHIGAN 48202
--------------------------------------------------------------------------------
(Address of principal executive offices)
Registrant's telephone number, including area code (313) 873-0200
-------------------------
================================================================================
QUEST BIOTECHNOLOGY, INC. AND SUBSIDIARIES
(A Company in the Development Stage)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
A. i) Effective January 18, 2001 BDO Seidman, LLP resigned from its
client-auditor relationship with Quest Biotechnology, Inc.
("the Company")
ii) BDO Seidman's audit opinion letter to the Company for the past
two fiscal years did not contain any adverse opinions,
disclaimer opinions and was not modified due to uncertainty,
audit scope or accounting principles. However, the auditor's
opinion letter included an explanatory paragraph in each of
the last two fiscal years regarding the Company's ability to
continue as a going concern.
iii) The decision to change accountants was not recommended by the
Company's board of directors.
iv) The Company has not had any disagreements with BDO Seidman on
any matter of accounting principles or practices, financial
statement disclosure or auditing scope.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
C. Exhibits:
i) Letter from BDO Seidman to the Commission
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
QUEST BIOTECHNOLOGY, INC.
-------------------------
REGISTRANT
/S/ LORNA M. O. ANDERSON
-------------------------------------
CHIEF FINANCIAL OFFICER
DATE: JANUARY 22, 2001
3